Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...
Hosted on MSN2mon
Dr Reddy's Q3 Preview: PAT may rise 10% YoY; US sales to be stableDF sales are likely to grow 15% YoY to Rs 1,400 crore driven by the integration of the Sanofi portfolio ... 12.5% YoY led by strong growth in Gastro/Derma/Vaccines and in-licensing opportunities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback